



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



LipidLaunch™ LP-01 LNP (Luciferase)

Item No. 39896

Overview and Properties

Synonym: LipidLaunch™ CIN-16645 LNP (Luciferase)


Storage: -80°C (as supplied)

Stability: ≥6 months

Supplied in: TBS, pH 7.5, with 10% sucrose

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Images



LNP Characterization Parameters	
Size	75-150 nm
Polydispersity index (PDI)	<0.2
Encapsulation efficiency (%EE)	>85%
mRNA concentration	Batch specific, 25-100 µg/ml
mRNA/vial	5 µg

Transfection of cells with luciferase-encapsulating LP-01 particles. Huh7 hepatocytes (left), and A549 lung epithelial cells (right), were incubated with Cayman's LipidLaunch™ LP-01 LNP (Luciferase) (Item No. 39896) at indicated RNA concentrations for 24 hours in culture cell media with 10% FBS. Luciferase expression (RLU) is shown.

Description

LipidLaunch™ LP-01 LNP (Luciferase) is a solution containing lipid nanoparticles (LNPs) composed of the ionizable cationic amino lipid LP-01 (Item No. 37278), cholesterol (Item Nos. 9003100 | 39088), the phospholipid 1,2-distearoyl-sn-glycero-3-PC (Item Nos. 15100 | 39189), and the lipid excipient DMG-PEG(2000) (Item No. 33945) at a molar ratio of 45:44:9:2 and encapsulating mRNA encoding firefly luciferase protein. It is intended for proof-of-concept experiments to determine whether LP-01-based LNPs can effectively lead to the expression of a protein of interest in a target cell type, either *in vitro* or *in vivo*. Firefly luciferase is an enzyme that catalyzes the oxidation of ATP-dependent D-luciferin, resulting in chemiluminescence at a wavelength of approximately 560 nm.

Suggested *in vitro* use: Thaw LNPs on ice with occasional gentle swirling (*do not vortex*). Using a gentle pipetting technique, dilute 1:100-1:500 in complete cell culture media (with serum) and add to subconfluent cells in a luminescence-compatible tissue culture plate. Use a luciferase reporter assay substrate and read luminescence on a plate reader. Optimal conditions are highly dependent on cell type.

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/15/2024

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM